New Research from the CWMH: Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

New Research from the CWMH: Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

By |2016-03-29T15:29:06+00:00August 1st, 2015|General, New Research|0 Comments

Dyslipidemia is a common side effect of atypical antipsychotics and, for a significant number of patients, may limit the acceptabillily of this class of drugs as an option for long-term treatment. This open trial tested the efficacy of omega-3 fatty acids for treating dyslipidemia associated with the use of atypical antipsychotics. Participants had hypertriglyceridemia (> 200 mg/dL) and/or hypercholesterolemia (> 250 mg/dL) and were treated with omega-3 fatty acids (Lovaza) for up to 16 weeks.

Omega-3 supplementation reduced triglyceride levels but did not affect levels of total cholesterol.

Freeman MP, McInerney K, Sosinsky AZ, Kwiatkowski MA, Cohen LS. Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia. Ann Clin Psychiatry. 2015 Aug;27(3):197-202.

Leave A Comment